Table 1.
Baseline characteristics.
| AdjC |
NAC |
|||
|---|---|---|---|---|
| N = 9000 | (%) | N = 5520 | (%) | |
| Age | ||||
| −65 | 5891 | 65.5 | 4481 | 81.2 |
| 66–70 | 1366 | 15.2 | 625 | 11.3 |
| 71- | 1743 | 19.4 | 414 | 7.5 |
| Menopausal status | ||||
| Premenopause | 2339 | 26.0 | 2257 | 40.9 |
| Postmenopause | 6404 | 71.2 | 3111 | 56.4 |
| Unknown | 257 | 2.9 | 152 | 2.8 |
| BMI (kg/m2) | ||||
| −25.0 | 7016 | 78.0 | 4200 | 76.1 |
| 25.0< | 1984 | 22.0 | 1320 | 23.9 |
| Histology | ||||
| IDC | 7438 | 82.6 | 5016 | 90.9 |
| Medullary or adenoid cystic carcinoma | 261 | 2.9 | 72 | 1.3 |
| Others | 1301 | 14.5 | 432 | 7.9 |
| Tumor diameter | ||||
| 0.1–2.0 cm | 3665 | 40.7 | 1030 | 18.7 |
| 2.1–5.0 cm | 4653 | 51.7 | 3620 | 65.6 |
| 5.1 cm- | 499 | 5.5 | 800 | 14.5 |
| Unknown | 183 | 2.0 | 70 | 1.3 |
| Clinical T status | ||||
| T1 | 4349 | 48.3 | 1159 | 21.0 |
| T2 | 4174 | 46.4 | 3445 | 62.4 |
| T3 | 294 | 3.3 | 475 | 8.6 |
| T4b | 183 | 2.0 | 441 | 8.0 |
| Clinical N status | ||||
| N0 | 7118 | 79.1 | 2628 | 47.6 |
| N1 | 1678 | 18.6 | 2402 | 43.5 |
| N2 | 204 | 2.3 | 490 | 8.9 |
| ER | ||||
| Negative | 7972 | 88.6 | 4,840 | 87.7 |
| 1–9 % | 654 | 11.4 | 680 | 12.3 |
| PgR | ||||
| Negative | 8,346 | 92.7 | 5,155 | 93.4 |
| 1–9 % | 654 | 7.3 | 365 | 6.6 |
| HER2 | ||||
| Score 0 | 5011 | 55.7 | 3031 | 54.9 |
| Score 1 | 2867 | 31.9 | 1830 | 33.2 |
| Score 2 and FISH negative | 1122 | 12.5 | 659 | 11.9 |
| Annual breast cancer cases per facility | ||||
| −99 | 3678 | 40.9 | 1655 | 30.0 |
| 100- | 5322 | 59.1 | 3865 | 70.0 |
Abbreviations: BMI = body mass index; IDC = invasive ductal carcinoma; ER = estrogen receptor; PgR = progesterone receptor; HER2 = human epidermal growth receptor 2; FISH = Fluorescence in situ hybridization.